InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. is a pharmaceutical drug development company focused on creating small molecule drug candidates. These candidates are designed to interact with CB1 and CB2 receptors, which are part of the endocannabinoid system found throughout the human body, as well as other receptor targets linked to human diseases. CB1 receptors are mainly in the brain and central nervous system, while CB2 receptors help regulate neuroinflammation and immune responses. The company's research aims to treat diseases with significant unmet medical needs. On March 4, 2026, InMed's Board approved the decision to close down BayMedica's commercial operations business segment. This segment was InMed's only revenue-generating commercial operation. By June 30, 2026, BayMedica had ceased all operating activities, and its two remaining employees left on July 31, 2026. A commercial lease for BayMedica will end in August. Following the closure of commercial operations, InMed's activities have focused on the preclinical development of its product candidates: INM-901 for Alzheimer's disease, INM-089 for dry Age-related Macular Degeneration (dry AMD), and INM-755 (cannabinol) cream. InMed does not currently plan to allocate substantial resources to advancing these product candidates, and further development would depend on securing additional financing. The company has developed a library of novel, proprietary drug candidates, which are patentable new chemical entities (NCEs) for pharmaceutical development. Its current potential pharmaceutical pipeline includes three programs targeting Alzheimer's disease, dry AMD, and Epidermolysis Bullosa (EB).